l e t t e r s
Genomic analyses promise to improve tumor characterization to optimize personalized treatment for patients with hepatocellular carcinoma (HCC). Exome sequencing analysis of 243 liver tumors identified mutational signatures associated with specific risk factors, mainly combined alcohol and tobacco consumption and exposure to aflatoxin B 1 . We identified 161 putative driver genes associated with 11 recurrently altered pathways. Associations of mutations defined 3 groups of genes related to risk factors and centered on CTNNB1 (alcohol), TP53 (hepatitis B virus, HBV) and AXIN1. Analyses according to tumor stage progression identified TERT promoter mutation as an early event, whereas FGF3, FGF4, FGF19 or CCND1 amplification and TP53 and CDKN2A alterations appeared at more advanced stages in aggressive tumors. In 28% of the tumors, we identified genetic alterations potentially targetable by US Food and Drug Administration (FDA)-approved drugs. In conclusion, we identified risk factor-specific mutational signatures and defined the extensive landscape of altered genes and pathways in HCC, which will be useful to design clinical trials for targeted therapy.
HCC is a heterogeneous disease that usually develops within liver cirrhosis related to various etiologies. HBV infection, with or without aflatoxin B 1 (AFB 1 ) exposure, is the most frequent etiology in Asia and Africa, whereas hepatitis C virus (HCV) infection, chronic alcohol abuse and metabolic syndrome are frequently related to HCC in Western countries 1, 2 . In cirrhosis, hepatocarcinogenesis is a multiple-step process where precancerous dysplastic macronodules (DMNs) transform into early HCCs that progress into 'small and progressed HCCs' , then lead to advanced HCC 3, 4 . In rare cases, HCC develops in normal liver, with some of these tumors potentially resulting from malignant transformation of hepatocellular adenomas (HCAs) [5] [6] [7] . Unraveling the patterns of genomic alterations in these heterogeneous tumors is pivotal in identifying targeted therapies that could improve patient care 8, 9 .
To understand HCC diversity, we analyzed the whole coding sequences of 243 liver tumors surgically resected in Europe (France, Italy and Spain) associated with cirrhotic (METAVIR F4, n = 118), fibrotic (F2-F3, n = 46) or non-fibrotic (F0-F1, n = 79) livers 10 . Various risk factors were identified, including alcohol intake (41%), HCV infection (26%), non-alcoholic steatohepatitis (NASH) as a co-occurrence of metabolic syndrome (18%), HBV infection (14%), hemochromatosis (7%) and no known etiology (11%). The 118 tumors associated with cirrhosis represented different stages along HCC progression, including 7 DMNs and 7 early, 17 small and progressed, 58 classic and 29 poor-prognosis HCCs (see the Online Methods and Supplementary Tables 1 and 2 for clinical definitions). We performed exome sequencing in tumors and matched non-tumor liver samples to a mean depth of 72-fold (Supplementary Fig. 1 ). We identified 28,478 somatic mutations, 6 ,184 of which occurred in a single tumor with Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets l e t t e r s a hypermutation phenotype (Supplementary Table 3) . Excluding this sample, we identified a median of 21 silent and 64 non-silent mutations per tumor (ranging from 1 to 706 mutations in total), corresponding to a mean somatic mutation rate in coding sequences of 1.3 mutations per megabase, consistent with previous reports [11] [12] [13] . We analyzed the mutational spectrum of the 243 liver tumors to identify mutagenic processes operative in HCC. De novo signature analysis using the Wellcome Trust Sanger C>A C>G C>T  T>A T>C T>G  C>A C>G C>T  T>A T>C T>G   C>A C>G C>T  T>A T>C T>G  C>A C>G C>T  T>A T>C T>G  C>A C>G C>T  T>A T>C T>G   C>A C>G C>T  T>A T>C T>G  C>A C>G C>T  T>A T>C T>G  C>A C>G C>T  T>A TERT  CTNNB1  TP53  ARID1A  ALB  AXIN1  APOB  CDKN2A  ARID2  RPS6KA3  DST  NFE2L2  ATM  MLL2  MAP1B  TSC2  FRAS1  ATP10B  FGF-CCND1  ACVR2A  HNF1A  ASPM  NAV3  PTPRB  DMD  FAT4  SYNE2  KEAP1  RB1 PEG3 DOCK2 Figure 2 Integration of mutations, focal amplifications and homozygous deletions identifies putative driver genes in HCC.
(a) The 161 putative driver genes identified by integrating mutations and focal CNAs are presented, with log-transformed mutation significance on the x axis and the net frequency of gains and deletions on the y axis. KIT 1%
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Chromatin-remodeling complexes 28% Figure 3 The landscape of altered genes and pathways in HCC. Shown are the 11 pathways altered in ≥5% of HCCs. Genes belonging to each pathway are represented with their alteration frequencies (green font, inactivation; orange font, activation; white font, unknown), and activating or inhibiting interactions between pathways are highlighted. Major genes lacking alterations are highlighted in white. Focal amplifications (FAs) and significant associations with etiologies are indicated. Potential druggable genes are assigned (yellow, FDA-approved drugs; lightning symbols, drugs screened in phase I-III clinical trials).
npg l e t t e r s associated with demographic, etiological and molecular features ( Fig. 1b-d and Supplementary Tables 4 and 5). MSig1 included nine HCCs enriched in signature 4 (frequent C>A and dinucleotide mutations), which has previously been shown to be associated with tobacco use 14, 17 . The prevalence of smokers in MSig1 was high (57%) but not significantly different from that for the other groups. The MSig2 group (five HCCs) was characterized by the new signature 24 showing a high rate of C>A mutations. All of the patients in the MSig2 group were migrants born in subtropical African countries and infected by HBV. Three of these tumors displayed a somatic TP53 mutation encoding p.Arg249Ser typical of AFB 1 -exposed HCC 18, 19 , suggesting that signature 24 reflects the mutational pattern induced by AFB 1 . There was an equal prevalence of mutations for signatures 5 and 16 (49% each) in MSig3. This particular group included 19 highly mutated HCCs associated with alcohol and tobacco exposure (67%; P = 6 × 10 −5 , Fisher's exact test), CTNNB1 mutation (74%; P = 8 × 10 −4 ) and non-cirrhotic livers (79%; P = 0.02). These results suggest a genotoxic, synergistic effect of alcohol and tobacco exposures in 8% of the patients who developed a homogeneous molecular subtype of tumors. MSig4 tumors were characterized by frequent TP53 mutations and signature 5, enriched in T>C transitions. Mutations in the 46 tumors classified in MSig5 were related to signatures 1A and 1B, resulting from spontaneous deamination at NCG trinucleotides (where the underlined nucleotide is mutated) acquired through the patient's lifetime 14 . This group of tumors demonstrated a low mutation rate and an early histological stage, but these tumors also had lower tumor cell content, so this group may partly be related to normal cell contamination (Online Methods). Signature 16 accounted for 79% of mutations in MSig6 tumors and was associated with older patients and with TERT and CTNNB1 mutations. Among the tumors classified as singletons, one (BCM723T) showed mutations from signature 6, which is characteristic of cancers with defective DNA mismatch repair, displaying numerous indels. The newly identified signature 23 was only encountered in the hypermutated tumor CHC892T, occurring in a 71-year-old female presenting with a non-fibrotic liver having black anthracotic pigment deposition, predominantly in macrophages and vessels ( Supplementary Fig. 4 ). This signature was characterized by a predominance of C>T mutations with a strong strand bias that may result from the interplay between an unknown mutagenic process affecting predominantly guanine residues and transcription-coupled nucleotide excision repair 15 . To validate the mutational signatures identified in our series, we analyzed the mutation patterns identified by exome sequencing in the International Cancer Genome Consortium (ICGC)-Japan (452 tumors) 20 and The Cancer Genome Atlas (TCGA) cohorts of 198 tumors. Consistent with the study by Totoki et al. 20 , we found an enrichment of T>C mutations in an ATN context in the Japanese data. We also found two tumors with mutational patterns corresponding to our signatures 6 and 23, validating the occurrence of these signatures in rare HCC cases (Supplementary Fig. 5 ). Six tumors in the TCGA data clustered with our MSig2 cases and displayed patterns similar to the AFB 1 -related signature 24. These cases were all African or Asian (P = 0.002, Fisher's exact test), and three of them displayed the characteristic TP53 mutation encoding p.Arg249Ser (P = 8 × 10 −4 , Fisher's exact test) (Supplementary Fig. 6 ).
We used MutSigCV to identify cancer driver genes 21 . Fourteen genes were significantly enriched for damaging mutations (q < 0.05; Table 6 ). We also analyzed copy number alterations (CNAs) by comparing sequence coverage in the 243 tumors and matched non-tumor liver samples. The pattern of broad gains and losses was consistent with previous reports in HCC (Fig. 2b) 11, 22, 23 . Figure 4 Major clusters of associated alterations. Shown are the three major groups of associated alterations: the CTNNB1 cluster, the AXIN1 cluster and the TP53 cluster. Significant associations and exclusions between genes are represented, with line widths proportional to significance, as indicated. Outline colors for each gene indicate its participation in a particular pathway. Table 8) .
To identify cellular pathways associated with HCC, we annotated the 161 candidate driver genes using the Gene Ontology (GO) database and manually curated the precise role of each gene in pathways (Online Methods). We found 11 pathways altered in ≥5% of HCCs ( Fig. 3 and Supplementary Figs. 7-9 ): TERT promoter mutations activating telomerase expression (60%) 24 , WNT/β-catenin (54%), phosphoinositide 3-kinase (PI3K)-AKT-mTOR (51%), TP53/cell cycle (49%), mitogen-activated protein kinase (MAPK) (43%), hepatic differentiation (34%), epigenetic regulation (32%), chromatin remodeling (28%), oxidative stress (12%), interleukin (IL)-6/JAK-STAT (9%) and transforming growth factor (TGF)-β (5%). This analysis identified new genes recurrently mutated in HCC: β-catenin inhibitors (ZNRF3, USP34 and MACF1), hepatocyte-secreted proteins (APOB and FGA) and the TGF-β receptor ACVR2A, recently associated with chondrosarcoma 25 . We then identified significant associations between mutations and risk factors (Supplementary Table 9 ). Alcohol-related HCCs were significantly enriched in CTNNB1, TERT, CDKN2A, SMARCA2 and HGF alterations (P < 0.05, χ 2 tests for trend in proportions). HBV-related HCCs were frequently mutated in TP53, and we exclusively identified IL6ST mutations in HCCs with no known etiology. In contrast, HCV infection, metabolic syndrome and hemochromatosis did not show significant associations.
Because each tumor accumulates numerous damaging mutations, we identified three major clusters of associated alterations, centered on CTNNB1, AXIN1 and TP53 (Fig. 4, Supplementary Fig. 10 and Supplementary Table 10 ). Interestingly, alterations of genes belonging to the same pathway were frequently distributed in different clusters. These results may reflect cooperation, functional redundancy or lethality of gene combinations and may contribute to better predicting the efficacy of targeted therapies.
Next, we defined the catalog of actionable genomic alterations among the 11 major pathways. Altogether, 28% of patients harbored at least one damaging alteration potentially targetable by an FDA-approved drug (Fig. 3, Supplementary Fig. 11 and Supplementary Table 11) , and 86% harbored a mutation targetable by a drug studied in phase I to phase III clinical trials ( Supplementary  Fig. 11 and Supplementary Table 12) . Alterations targetable by FDAapproved drugs comprised focal amplifications or mutations of FLT
, JAK1 (<1%) and KDR (<1%). We also showed in vitro that inactivating mutations of RPS6KA3 (7%) induced activation of the RAS-MAPK pathway with increased levels of phosphorylated ERK1 and ERK2 (ERK1/2) (Supplementary Fig. 12 ), suggesting that RPS6KA3-mutated HCCs could be targeted by ERK or MEK inhibitors. Notably, advanced-stage tumors harbored more potentially targetable alterations, including, in particular, FGF-CCND1 amplifications (Supplementary Fig. 13) .
In addition to alterations in driver genes that can be directly inhibited by targeted drugs, other alterations might potentiate the drug sensitivity of cancer cells. These include changes to NQO1, which markedly increase sensitivity to the HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) by reducing this compound to a more potent inhibitor 26, 27 . NQO1 expression is induced by the oxidative stress pathway, which was activated in 12% of HCCs, primarily by mutations of KEAP1 or NFE2L2. To test whether these tumors could be more sensitive to HSP90 inhibitors, we assessed the response of 29 liver cancer cell lines to 17-AAG and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (Fig. 5a) . We found that growth inhibition of 50% (GI 50 ) was significantly inversely correlated with the expression of NQO1 (Pearson's r = −0.56, P = 0.0015; Fig. 5b) . Two of the three cell lines harboring KEAP1-inactivating mutations were highly sensitive to HSP90 inhibitors, whereas the third mutated cell line, which was less sensitive, was homozygous for the NQO1 mutation (NQO1*2 allele, rs1800566) encoding the p.Pro187Ser missense variant causing NQO1 deficiency (Fig. 5c) 28 . These findings suggest that tumors with high NQO1 expression may be more sensitive to HSP90 inhibitors, except in patients with a homozygous genotype encoding p.Pro187Ser.
Finally, we explored the progression of HCC in cirrhotic and non-cirrhotic livers. We identified an increased number of gene mutations (P = 1.2 × 10 −3 , Jonckheere-Terpstra test) and chromosome (Fig. 6a) . Although TERT promoter mutations were already frequent at early stages, CTNNB1 and TP53 mutation frequencies increased significantly with progression, and focal amplifications at the FGF-CCND1 locus were mostly encountered in poor-prognosis HCCs (P < 0.01, χ 2 test for trend in proportions; Fig. 6b) . Interestingly, chromosome aberrations appeared later than gene mutations during progression. Although we observed similar findings in tumors that developed in non-fibrotic liver with respect to the progressive accumulation of mutations and CNAs, TERT promoter mutations were later events during malignant transformation. Moreover, HNF1A and IL6ST mutations were restricted mostly to HCAs, suggesting that most of the HCCs in nonfibrotic liver did not derive from the transformation of an adenoma (Fig. 6b) . A link between FGF19 expression and overall survival has been described in the literature 22, 24, [29] [30] [31] [32] . Using a multivariate survival analysis, we found that CDKN2A inactivation and FGF-CCND1 amplification were associated with poor prognosis in our cohort of resected HCCs, independently of classical prognostic clinical and histological features ( Fig. 6c and Supplementary Table 13 ).
In conclusion, our study identified relationships between environmental exposures and mutational patterns in HCC as well as the landscape of driver genes and pathways altered in different clinical stages and etiological backgrounds. For patient care, genomic alterations identified in targetable genes will be useful to identify patients with HCC who could potentially benefit from targeted treatment in future clinical trials. Clinical data. Clinicopathological data were available for all cases. Risk factors were defined by substantial alcohol intake, HCV, HBV, hemochromatosis, no known etiology and NASH as co-occurrence of metabolic syndrome. Metabolic syndrome consists of a combination of disorders, including central obesity (waist circumference >102 cm (males), >88 cm (females)), hypertriglyceridemia (triglycerides >150 mg/dl), low high-density lipoprotein serum levels (<40 mg/dl), arterial hypertension (>130 mm Hg systolic or >85 mm Hg diastolic) and raised fasting plasma glucose (FPG) levels ≥1.1 mg/dl or previously diagnosed type 2 diabetes. At least three of the latter criteria had to be fulfilled for diagnosis. NASH can be the chronic consequence of nonalcoholic fatty liver disease (NAFLD), which frequently co-occurs in patients with metabolic syndrome and is characterized by hepatocellular accumulation of triglycerides in the absence of substantial alcohol consumption. By contrast, NASH additionally includes the presence of inflammation and can display different degrees of fibrosis. Patients without known etiology were those that did not display the above frequent etiologies or rare etiologies (such as primary biliary cirrhosis, autoimmune hepatitis and primary sclerosing cholangitis). Samples were classified according to clinical, pathological and genetic features as previously described by Guichard et al. (Supplementary Tables 1 and 2) 11 . In all HCC samples, the ratio of tumor cells to non-tumor cells was evaluated to be >50%; the PurBayes method 33 estimated an average of 70% (range of 39-100%) tumor purity on the basis of sequencing data (Supplementary Table 14) . Definition of DMN and early, small and progressed, classic and poor-prognosis HCCs was based on histopathological criteria in HCC proposed by the International Consensus Group for Hepatocellular Neoplasia 3,4 . DMN was defined by macronodules containing low-grade (a cell population lacking architectural atypia with a mild increase in cellularity as compared to the surroundings; portal tracts detectable) or high-grade (frank cytological and architectural atypia as compared to the surroundings but insufficient for a diagnosis of malignancy; portal tracts detectable) dysplastic nodules. Early HCC was defined by a diameter ≤2 cm and a vaguely nodular lesion with indistinct margins and a well-differentiated histology that might require careful distinction from high-grade dysplastic nodules; few portal tracts were detectable. Small and progressed HCC was defined by a diameter ≤2 cm and a distinctly nodular lesion with well-(G1) to moderately (G2) differentiated histology in which malignancy was recognized at first glance; no portal tracts were detectable. Poor-prognosis HCC was defined by HCC cases displaying recurrence within 2 years. Classic HCC was defined as non-early, non-small, non-poor prognosis HCC.
Genomic DNA extraction. We extracted DNA using a salting-out procedure 34 . Genomic DNA was loaded on a 0.8% agarose gel for quality control; only DNA >10 kb in size was selected. DNA quantification was performed using Hoechst 33258 from Sigma Chemical.
Exome capture, library construction and sequencing. Sequence capture, enrichment and elution for 243 pairs of genomic DNA were performed by IntegraGen as previously described in Guichard et al. with some modifications 11 . Agilent in-solution enrichment was used with the manufacturer's biotinylated oligonucleotide probe library (SureSelect Human All Exon kit v2-46Mb (n = 36 pairs), v3-52Mb (n = 7 pairs), v4-70Mb (n = 56 pairs) or v5+UTRs-75Mb (n = 144 pairs), Agilent Technologies) according to the manufacturer's instructions. The eluted enriched DNA sample was sequenced on an Illumina HiSeq 2000 sequencer as paired-end 75-base reads as previously described 35 . Image analysis and base calling were performed using Illumina Real-Time Analysis (RTA) Pipeline v1.12 with default parameters. Whole-exome sequencing pre-analysis was based on the Illumina pipeline (CASAVA1.8.2). Only the positions included in the bait coordinates were conserved. Each sample was sequenced to an average depth of 72.0×, with ~96.9% of the targeted regions covered by ≥1×, ~92.6% covered by ≥10× and ~82.9% covered by ≥25× (Supplementary Fig. 1 ). Table 3 ) considering only somatic mutations in coding regions plus consensus intronic bases (missense, nonsense, splice-site, indel and synonymous mutations) as previously described in Guichard et al. with some modifications 11 . Polymorphisms referenced in dbSNP135 or the 1000 Genomes Project with a minor allele frequency over 2% were removed. Functional evidence of predictive drastic consequences for the variants was investigated using PolyPhen-2 v2. 2.2 (ref. 36) . A total of 11,823 (41%) putative somatic mutations were validated manually using the Integrated Genomics Viewer (IGV), and 3,126 (11%) were validated using Sanger sequencing (Supplementary Table 3 ). Systematic Sanger sequencing was performed in a subset of 155 samples on a list of 11 genes (CTNNB1, TP53, ARID1A, AXIN1, RPS6KA3, CDKN2A, NFE2L2, ARID2, PI3KCA, KRAS and KEAP1), and we used these data to benchmark our exome mutation calling pipeline. A total of 151 somatic variants were called by both methods, whereas 21 variants were only identified by Sanger sequencing and 10 were only identified by exome sequencing. Variants not identified by exome sequencing were mostly mutations in the poorly covered, GC-rich exon 1 of ARID1A (n = 10 variants) and large deletions of CTNNB1 exon 3 (n = 3). These results yielded a sensitivity for our somatic mutation calling pipeline of 88% (82-92%, 95% confidence interval), which reached 95% (90-98%, 95% confidence interval) when excluding those two specific regions, and a specificity of 99% (98-100%, 95% confidence interval).
Identification of somatic variants. A list of variants was generated (Supplementary
Mutations were annotated using Alamut Batch, Alamut Visual v2.4 (Interactive Biosoftware) and Oncotator. All sequences have been deposited in the EGA database (accessions EGAS00001000217, EGAS00001000679 and EGAS00001001002) and the ICGC data portal.
De novo mutational signature analysis. The mutational catalogs of the 243 liver tumors were analyzed using the Wellcome Trust Sanger Institute mutational signatures framework 16 . This algorithm makes use of a well-known blind source separation technique, termed non-negative matrix factorization (NMF). NMF identifies the matrix of n mutational signatures, P, and the matrix of the exposures of these signatures, E, by minimizing a Frobenius norm while maintaining non-negativity:
|| || 2
The method for deciphering mutational signatures, including evaluation with simulated data and a list of limitations, can be found in ref. 16 . First, all mutation data were converted into a matrix M that was made up of 96 features comprising mutation counts for each mutation type (C>A, C>G, C>T, T>A, T>C and T>G; somatic mutations presented in a pyrimidine context) using each possible 5′ (C, A, G, T) and 3′ (C, A, G, T) context for all samples. Then, the algorithm was applied to the matrix that contained k mutation types and g samples, deciphering the minimal set of mutational signatures that optimally explained the proportion of each mutation type, thus estimating the contribution of each signature to each sample.
After extraction, four stable and reproducible mutational signatures were deciphered (see the stability and error plot in Supplementary Fig. 2 ) and termed signatures A, B, C and D. These signatures were compared to the catalog of 27 consensus signatures that were previously identified by a pan-cancer analysis encompassing 7,042 samples and 30 cancer types 14 . The comparison was performed by cosine similarity as described 16 as well as on the basis of other biological features exhibited by the mutational signatures (for example, transcriptional strand bias, presence of small insertions and/or deletions in a specific context, etc.).
The comparison showed that two of the four signatures were new, whereas the patterns of the remaining two signatures were previously identified through pan-cancer analysis. Notably, signature C exhibited a strong transcriptional strand bias of T>C mutations, especially at TA dinucleotides (70% versus 30%), a behavior consistent with that of signature 16. The pattern of mutations of signature C showed a cosine similarity of 0.95 with the pattern of mutations of signature 16. Similarly, the pattern for signature D was extremely similar to the one for signature 6 (cosine similarity of 0.90), with both exhibiting a prevalence of indels at repetitive elements. In contrast, signatures A and B had cosine similarity <0.90 with any of the previously identified mutational signatures. Please note that we previously used a cutoff of ~0.90 to cluster mutational signatures into consensus mutational signatures 14 .
Reintroduction of consensus mutational signatures and sample clustering. Previous analysis of 88 whole genomes from liver cancers identified 6 mutational signatures: signatures 1B, 4, 6, 12, 16 and 17 (ref. 14) . Further, signature 1B could be decomposed into signatures 1A and 5 (ref. 14). The de novo extraction of the mutational signatures of our 243 liver exomes identified 2 additional mutational signatures, termed signatures 23 and 24. Thus, the complete compendium of mutational signature that can be present in a liver cancer includes signatures 1A, 1B, 4, 5, 6, 12, 16, 17, 23 and 24. To evaluate the presence of all these signatures in the 243 liver exomes, we used a previously described approach to find the Exposure matrix minimizing the following constrained linear function for each sample 37 :
Here, Signature i    represents a vector with 96 components (corresponding to the 6 somatic substitutions and their immediate sequencing context) and Exposure i is a non-negative scalar reflecting the number of mutations contributed by this signature. n is equal to ten, and it reflects the number of all possible signatures that can be found in a liver sample. Any mutational signature contributing less than 1% of the somatic mutations in a sample was removed, and the sample was reanalyzed with the remaining signatures. Any signature that did not improve the cosine similarity between the original sample and the sample reconstructed using the consensus mutational signatures and their respective exposures by more than 0.02 was removed, and the sample was reanalyzed with the remaining signatures. The analysis showed that signatures 1A, 1B, 4, 5, 6, 16, 23 and 24 were present in these liver cancer exomes, whereas signatures 12 and 17 were not. Reintroduction allowed a better evaluation of the presence of mutational signatures in each sample by leveraging the set of consensus mutational signatures previously deciphered from a larger data set of 88 whole genomes.
All samples were clustered, on the basis of the number of somatic mutations contributed by each signature in each sample, using unsupervised hierarchical clustering with cosine distance and Ward linkage.
Copy number analysis.
To identify CNAs, we calculated the log ratio of the coverage in each tumor and its matched non-tumor liver sample for each bait of the exome capture kit. Log-ratio profiles were then smoothed using the circular binary segmentation algorithm as implemented in the Bioconductor package DNAcopy 38 . The most frequent smoothed value was considered to be the zero level of each sample. Segments with a smoothed log ratio above zero + 0.3 or below zero − 0.3 were considered to have gains and deletions, respectively. High-level amplification and homozygous deletion thresholds were defined as the mean + 5 s.d. of smoothed log ratios in regions with gains and deletions, respectively. Chromosome instability was quantified as the FAA, i.e., the proportion of chromosome arms with an aberrant copy number status along >60% of the length of each arm 11 .
Identification of putative driver genes. We first used the MutSigCV 21 algorithm to identify genes harboring significantly more mutations than expected by chance. This approach takes into account nucleotide context, gene expression, replication time, observed silent mutations and the presence of mutations in surrounding regions. It estimates the background mutation rate for each gene-patient category combination and tests the null hypothesis that all the observed mutations in each gene are a consequence of random background mutation. Genes for which this hypothesis was rejected on the basis of the Benjamini-Hochberg false discovery rate-corrected q value were considered significantly mutated. Analysis was carried out using default settings together with a liver-oriented covariates table comprising HCC-derived gene expression levels (Gene Expression Omnibus (GEO), GSE62232).
We then combined mutations and focal CNAs to define an enlarged list of putative drivers. We considered all genes with ≥6 alterations (non-silent mutations, high-level amplifications or homozygous deletions) among the 235 HCCs (excluding DMN samples and the hypermutated HCC sample, CHC892T), corresponding to a frequency of ≥2.5%. We then removed large genes (coding-sequence length ≤10,000 amino acids), genes not expressed in HCC when considering our Affymetrix microarray data set collected on a series of 81 HCCs (RMA-normalized intensities ≥20 units or <20 units, with ≥20 s.d.; GEO, GSE62232) and genes displaying a ratio of silent to non-silent mutations ≤0.15. In total, 161 genes passed 2 or more of these 3 filters and were considered to be putative driver genes (Supplementary Table 8 ).
Identification of recurrently altered pathways and targetable genes. Gene annotations, including unique gene and transcript identifiers, description and functional reports, were retrieved from Ensembl release 75 given the variant genomic location using the Bioconductor package biomaRt. The definition of the cellular pathways found to be associated with HCC was established by annotating the 161 candidate driver genes using the GO database and then stating their precise roles through an expert review of the literature and gene annotation or pathway databases including GeneCards, KEGG and PubMed. Using this approach, we identified 11 major pathways altered in more than 5% of HCCs. Some putative driver genes or genes already reported in HCC were added to the general scheme (Fig. 3a) , as well as genes with only minor or no alterations in our cohort but having key functional roles in the identified pathways. Interactions between pathways and repartitioning of the genes in the cellular compartments were highlighted as reported in the KEGG pathway database. The FDA-approved drugs or drugs screened in different phases of clinical trials that were found to be related to one of the genes or pathways were reviewed in the ClinicalTrails.gov and NCI Drug Dictionary databases.
Sanger sequencing. We confirmed 11% of the mutations identified by exome sequencing by independent PCR and Sanger sequencing. All HCC and liver cancer cell lines were systematically screened for mutations in CTNNB1, TP53, ARID1A, AXIN1, RPS6KA3, KEAP1, CDKN2A, NFE2L2, ARID2, PIK3CA and KRAS (Supplementary Table 15) as described in Guichard et al., and the promoter region of TERT was sequenced as described in Nault et al. 11, 24 . In all cases, the somatic origin of the mutation found in the tumor was verified by sequencing the corresponding adjacent, normal liver sample 11, 24 .
Cell lines. The 29 liver cancer cell lines were obtained from commercial sources. Cells were grown in DMEM or William's E medium supplemented with 10% FBS and 100 U/ml penicillin-streptomycin and were maintained at 37 °C in a humidified incubator in 5% CO 2 . Cell line identity was confirmed by exploring known gene mutations in each cell line. All the cells were free of mycoplasma, as tested by a PCR assay (Sigma).
Drugs and cell viability assays. 17-AAG and 17-DMAG, two benzoquinone ansamycin HSP90 inhibitors, were purchased from Sigma-Aldrich and dissolved in DMSO. Cells were seeded into 96-well plates at a density of 1,500-3,000 cells per well. After overnight incubation, cells were treated for 48 h with vehicle alone (0.1% DMSO) or with various concentrations of 17-AAG or 17-DMAG (0.001, 0.01, 0.1, 1 and 10 µM, in 0.1% DMSO) in 100 µl of culture medium supplemented with 10% FBS and 100 U/ml penicillin-streptomycin. Each concentration was tested in duplicate; experiments were repeated two to three times for each cell line. Cell viability was measured by MTS assays (Promega) according to the manufacturer's recommendations. The concentration of drug inhibiting cell growth by 50% relative to the untreated control (GI 50 ) was calculated after curve fitting with GraphPad Prism 5.0 software.
Cell line transfection and immunoblotting. Cells were transfected with 2 nM short interfering RNA (siRNA) using the Lipofectamine RNAiMAX reagent (Invitrogen) in six-well plates, according to the manufacturer's protocol. Three different siRNA duplexes targeting RPS6KA3 (encoding RSK2) (s12279, s12280 and s12280, Life Technologies) were tested. Block-iT Alexa Fluor Red npg
